West Pharmaceutical Services (WST) Earnings Date & Reports

Key Takeaways

• West Pharmaceutical Services (WST) reports third-quarter 2026 results before the market opens on Thursday, October 29, 2026.
• Management guided to Q3 net sales of $820 million to $835 million and adjusted diluted earnings per share (EPS) of $2.14 to $2.24.
• Analyst consensus sits near $2.18 in adjusted EPS, toward the upper end of the company's guided range.
• Reported growth faces a tough comparison from the divested SmartDose® 3.5mL business, which contributed roughly $30 million to third-quarter 2025 sales.
• Investors will focus on High-Value Product (HVP) Components, biologics, and GLP-1-related demand as the key growth drivers.

Earnings Context and Why It Matters

West Pharmaceutical Services is a leading supplier of components and delivery systems for injectable medicines, positioning it as a bellwether for pharmaceutical packaging and drug-delivery demand. Its third-quarter report matters because it tests whether the momentum from the first half of 2026, when organic sales grew by double digits and the company raised full-year guidance twice, is durable. Investors are watching whether High-Value Product components, biologics, and GLP-1 (glucagon-like peptide-1, the drug class behind leading obesity and diabetes treatments) demand continue to support a mix shift toward higher-margin products, even as a divestiture and foreign-exchange effects create reported-growth headwinds.

Earnings Expectations

West guided third-quarter 2026 net sales to a range of $820 million to $835 million, implying reported growth of 1.9% to 3.8% and organic growth of 7.0% to 8.9%. The company also guided adjusted diluted EPS to $2.14 to $2.24. The wide gap between reported and organic growth reflects the exclusion of the SmartDose® 3.5mL on-body delivery system, which was sold to AbbVie and generated about $30 million in net sales in the prior-year quarter, along with an estimated one-percentage-point foreign-currency headwind.

Wall Street consensus for the quarter sits near $2.18 in adjusted EPS, in line with the upper portion of management's guided range. For context, West has exceeded expectations in recent quarters: second-quarter 2026 adjusted EPS of $2.37 beat the $2.08 consensus, while first-quarter adjusted EPS of $2.13 came in well above forecasts. Full-year 2026 guidance, raised in July, calls for net sales of $3.345 billion to $3.380 billion and adjusted diluted EPS of $8.85 to $9.05.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like West Pharmaceutical Services, the AI Screener can help surface comparable names and momentum patterns across the medical equipment and supplies industry.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report is broadly constructive. West has posted consecutive top- and bottom-line beats in 2026 and raised guidance twice, and the stock has advanced more than 30% year-to-date through early October, including a rise of roughly 5.9% since the late-July second-quarter release.

Still, investors are mindful of several near-term risk factors. The SmartDose® divestiture suppresses reported growth comparisons, while lingering effects from a cybersecurity incident earlier in the year temporarily pressured the West Vantage contract-manufacturing segment. Inflationary costs, tariffs, and foreign-exchange fluctuations also remain potential drags on margins. How management frames fourth-quarter demand and the sustainability of biologics and GLP-1 momentum will likely shape the post-earnings response.

Forward Outlook and Key Factors to Monitor

Following the third-quarter release, investors should watch whether West reaffirms or adjusts its full-year 2026 guidance. The company has already signaled full-year organic sales growth of 10% to 11% and adjusted diluted EPS of $8.85 to $9.05, with management targeting more than 200 basis points of operating-margin expansion versus 2025.

High-Value Product Components will remain the central story. This category now represents roughly half of total company sales, and management expects the broader HVP Components business, including both GLP-1 and non-GLP-1 products, to grow in the high-teens range for the year. Continued strength in biologics, where West reports a high win rate on new large-molecule drug approvals, supports that outlook.

Other factors worth monitoring include the pace of recovery in the West Vantage segment following the cybersecurity incident, capital spending within the guided $250 million to $275 million range, and the timing of any additional share repurchases after the company bought back shares aggressively in the first half of 2026. Foreign-currency movements and tariff-related cost pressures could also influence margins in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations